Loading…
Trinity Biotech plc is projected to rise to $0.7039 by 2027, a +4% move from its current price of $0.6797. TRIB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.6559 | $0.6793 | $0.7036 | -0.05% |
| May 30 | $0.6461 | $0.679 | $0.7135 | -0.11% |
| May 31 | $0.6386 | $0.6786 | $0.7211 | -0.16% |
| Jun 1 | $0.6323 | $0.6782 | $0.7276 | -0.21% |
| Jun 2 | $0.6267 | $0.6779 | $0.7332 | -0.27% |
| Jun 3 | $0.6217 | $0.6775 | $0.7383 | -0.32% |
| Jun 4 | $0.6171 | $0.6772 | $0.743 | -0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6171 | $0.6772 | $0.743 | -0.37% |
| Week 2 | $0.5916 | $0.6746 | $0.7693 | -0.75% |
| Week 3 | $0.5723 | $0.6721 | $0.7893 | -1.12% |
| Week 4 | $0.5561 | $0.6696 | $0.8062 | -1.49% |
| Week 5 | $0.542 | $0.6671 | $0.821 | -1.86% |
| Week 6 | $0.5294 | $0.6646 | $0.8343 | -2.23% |
| Week 7 | $0.5179 | $0.6621 | $0.8464 | -2.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Trinity Biotech plc is a healthcare company that develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market in the Americas, Asia, Africa, and Europe. It provides clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners.
Trinity Biotech plc It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a PCR-based epigenetic liquid biopsy test for monitoring the risk of prostate cancer progressing to aggressive forms of the disease.
Trinity Biotech plc (TRIB) is a healthcare stock with a current price of $0.6797 and a market cap of $13.76M. It holds a position in the small-cap segment and is ranked 5008. The stock operates in the healthcare sector, focusing on clinical laboratory and POC diagnostic products across multiple regions.
The current price and fundamentals place it in a highly speculative, small-cap niche with potential upside reflected in the projected price path. The forecast indicates a long-run trajectory of rising average prices and notable upside by 2040 and 2050, though near-term results remain modest.
A major floor 28.4% below — a decisive break under it would weaken the trend.
The nearest floor, 16.1% below — buyers have tended to step in here.
The nearest ceiling, 10.3% above — a clean break opens room to run.
A major ceiling 38.3% above — clearing it would confirm fresh momentum.
Key TRIB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TRIB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.632 | Buy | $0.6376 | Buy |
| MA 10 | $0.604 | Buy | $0.6201 | Buy |
| MA 20 | $0.603 | Buy | $0.6176 | Buy |
| MA 50 | $0.6324 | Buy | $0.6455 | Buy |
| MA 100 | $0.6963 | Sell | $0.7062 | Sell |
| MA 200 | $0.8944 | Sell | $0.8053 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.32 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 282.05 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 11.48 | Buy |
| Bollinger %B (20,2) | 1.24 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.35 | Sell |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 72.96 | Sell |
| Momentum (10) | 0.09 | Buy |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 0.66 | Buy |
| ADX (14) | 16.92 | Neutral |
| ATR (14) | 0.02 | Info |
Sentiment is bullish, with RSI(14) at 60 and price activity constrained between near-term supports and resistances. The 50-day simple moving average sits at $0.6324, while the 200-day simple moving average is at $0.8944. A key near-term support level is $0.57 and a resistance level is $0.75.
Over the last 30 days, the price ranged from a low of $0.5393 to a high of $0.8566, reflecting a constructive but cautious interim picture.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.54 | $0.6797 | $0.8046 | 0% | Neutral | |
| $0.5428 | $0.7039 | $0.9755 | +4% | Neutral | |
| $0.6493 | $0.8728 | $1.26 | +28% | Bullish | |
| $0.673 | $0.9327 | $1.40 | +37% | Bullish | |
| $0.6793 | $0.9674 | $1.49 | +42% | Bullish | |
| $0.6577 | $0.9602 | $1.52 | +41% | Bullish | |
| $0.6457 | $0.9652 | $1.56 | +42% | Bullish | |
| $0.6393 | $0.9771 | $1.62 | +44% | Bullish | |
| $0.7566 | $1.18 | $1.99 | +74% | Bullish | |
| $0.9172 | $1.46 | $2.50 | +115% | Bullish | |
| $1.00 | $1.76 | $3.24 | +158% | Bullish | |
| $1.32 | $2.73 | $5.59 | +302% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.54 | $0.6797 | $0.7969 | +0.00% |
| June 2026 | $0.5472 | $0.6466 | $0.7852 | -4.87% |
| July 2026 | $0.5418 | $0.6473 | $0.7996 | +0.11% |
| August 2026 | $0.5387 | $0.649 | $0.8123 | +0.27% |
| September 2026 | $0.5038 | $0.6114 | $0.7733 | -5.80% |
| October 2026 | $0.4815 | $0.5881 | $0.7511 | -3.80% |
| November 2026 | $0.4974 | $0.611 | $0.7869 | +3.89% |
| December 2026 | $0.5018 | $0.6198 | $0.8046 | +1.45% |
Click any year to see its month-by-month TRIB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect TRIB to range from $0.54 to $0.8046 through 2026. The $0.6797 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The TRIB price prediction for 2027 points to an average of $0.7039 (low $0.5428, high $0.9755) — a potential gain of +4% on today's $0.6797. A consolidation phase looks the most probable path here.
In 2028, TRIB is projected to trade between $0.6493 and $1.26, averaging $0.8728 — a potential gain of +28% from today's $0.6797. That is up +24% on the projected 2027 average. Momentum favours further upside here.
Trinity Biotech plc's 2029 outlook centres on $0.9327, within a $0.673 to $1.40 range. That is up +7% on the projected 2028 average. That marks a +37% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, TRIB could reach as high as $1.49, with a base case around $0.9674 and support toward $0.6793 — roughly +42% from $0.6797. Momentum favours further upside here.
Expect TRIB to range from $0.6577 to $1.52 through 2031. The $0.9602 average target implies a +41% move from current prices. That is -1% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
The TRIB price prediction for 2032 points to an average of $0.9652 (low $0.6457, high $1.56) — a potential gain of +42% on today's $0.6797. Momentum favours further upside here.
In 2033, TRIB is projected to trade between $0.6393 and $1.62, averaging $0.9771 — a potential gain of +44% from today's $0.6797. That is up +1% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Trinity Biotech plc's 2034 outlook centres on $1.18, within a $0.7566 to $1.99 range. That is up +21% on the projected 2033 average. That marks a +74% change versus current levels. Momentum favours further upside here.
By 2035, TRIB could reach as high as $2.50, with a base case around $1.46 and support toward $0.9172 — roughly +115% from $0.6797. Buyers look set to stay in control over this stretch.
Expect TRIB to range from $1.00 to $3.24 through 2040. The $1.76 average target implies a +158% move from current prices. That is up +20% on the projected 2035 average. Momentum favours further upside here.
The TRIB price prediction for 2050 points to an average of $2.73 (low $1.32, high $5.59) — a potential gain of +302% on today's $0.6797. Buyers look set to stay in control over this stretch.
Investing $1,000 in TRIB today (≈ 1,471.237311 TRIB) could be worth
$4,020.41
+$3,020.41 (+302%) by 2050 · US Dollar
Based on the average projected TRIB price of $2.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TRIBwould be worth at today's price.
$1,000 invested in TRIB on May 27, 2025 (≈ 1,492.537276 TRIB) would be worth
$1,014.48
+$14.48 (+1.4%) today · 1.01× · US Dollar
Based on a TRIB entry price of $0.67 vs. today's $0.6797.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.6 | $1,132.83 | +13.3% |
| 1 month ago | $0.64 | $1,062.03 | +6.2% |
| 3 months ago | $0.72 | $944.03 | -5.6% |
| 6 months ago | $1.05 | $647.33 | -35.3% |
| 1 year ago | $0.67 | $1,014.48 | +1.4% |
| All time (5.0y) ago | $16.65 | $40.82 | -95.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TRIB forecast.
Our base-case forecast reaches $1.40 around 2035.
Implied market cap at $1.40: $28.35M
The multi-year forecast shows a path of gradual upside, with the average price rising from $0.6797 in 2026 toward higher levels in subsequent years. The 2027 avg is $0.7039 (ROI 3.6%), 2028 avg $0.8728 (ROI 28.4%), and 2029 avg $0.9327 (ROI 37.2%). By 2030, the avg is projected to $0.9674 with a 42.3% ROI, and 2031–2033 show continued bullish momentum (avg $0.9602–$0.9771, ROI 41.3–43.8%).
The forecast strengthens into 2034–2035 with substantial upside (avg up to $1.46 in 2035 and max prices reaching $2.50), and then accelerates further through 2040 (avg $1.76, ROI 158.4%, max $3.24) and 2050 (avg $2.73, ROI 302%, max $5.59). These figures imply meaningful upside potential but remain estimates, not guarantees, and outcomes depend on factors not captured here. The outlook reflects bullish sentiment in later years, balanced by inherent uncertainty.
Tap a question to reveal the answer.
In 2030 the forecast shows an avg price of $0.9674 with a min of $0.6793 and a max of $1.49, and a ROI of 42.3%. The sentiment for 2030 is BULLISH.
The forecast includes positive ROI starting in 2027 (3.6%), rising to 28.4% in 2028, 37.2% in 2029, and 42.3% in 2030, with continued gains in later years. These are estimates and not guarantees.
The forecast shows a max of $1.99 in 2034 and $2.50 in 2035, indicating a potential to reach or exceed $2 in the mid-2030s, subject to market factors.
Current price is $0.6797 and market cap is $13.76M.
The 30-day range was $0.5393 to $0.8566.
Trinity Biotech plc Community Discussion
0Share your Trinity Biotech plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.